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Altered macrophage infiltration upon tissue damage results in inadequate healing due to
inappropriate remodeling and stem cell recruitment and differentiation. We investigated
in vivo whether cells of endothelial origin phenotypically change upon heterotopic
ossification induction and whether infiltration of innate immunity cells influences their
commitment and alters the ectopic bone formation. Liposome-encapsulated clodronate
was used to assess macrophage impact on endothelial cells in the skeletal muscle upon
acute damage in the ECs specific lineage-tracing Cdh5CreERT2:R26REYFP/dtTomato
transgenic mice. Macrophage depletion in the injured skeletal muscle partially shifts
the fate of ECs toward endochondral differentiation. Upon ectopic stimulation of
BMP signaling, monocyte depletion leads to an enhanced contribution of ECs
chondrogenesis and to ectopic bone formation, with increased bone volume and density,
that is reversed by ACVR1/SMAD pathway inhibitor dipyridamole. This suggests that
macrophages contribute to preserve endothelial fate and to limit the bone lesion in a
BMP/injury-induced mouse model of heterotopic ossification. Therefore, alterations of
the macrophage-endothelial axis may represent a novel target for molecular intervention
in heterotopic ossification.
Keywords: macropahge, endothelial cell (EC), heterotopic ossification (HO), EndoMT, endothelial progenitors
cells, RNASeq and NGS data analysis, micro-computerized tomography (µCT) analysis
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INTRODUCTION
The regenerating skeletal muscle niche is a complex environment
where distinct cell populations play crucial and non-redundant
roles. Progenitors in the muscle comprise the satellite cells, which
are quiescent stem cells that, once activated, are the primary
myogenic cells responsible for skeletal muscle regeneration (1).
Vascular progenitors and interstitial cells, such as fibroadipogenic
precursors (FAPs) and PW1+/Pax7− interstitial progenitor cells
(PICs), contribute to muscle regeneration in several ways. They
induce the formation of the new capillary network to provide
nutrients and oxygenation, they directly differentiate to muscle
fibers (2, 3) and produce growth factors and other soluble signals
essential for proper stem cell activation, myogenic differentiation
and reconstitution of the contractile apparatus (4–7). Disruption
of vessel assembly and jeopardized angiogenesis concur tomuscle
wasting (8, 9).
Increasing evidences support the hypothesis that these
interactions and processes need to be orchestrated and
coordinated by the cells of the immune system, in particular
macrophages (MPs), that infiltrate the muscle immediately
after the initial tissue injury and necrosis and release several
cytokines (10, 11). The two main macrophage populations, i.e.,
the classically activated inflammatory MPs and the alternatively
activated MPs, play a sequential role to set the pace of
muscle regeneration upon acute injury (11–14). Failure of
macrophage recruitment or altered polarization results in
impaired tissue regeneration and fibrosis, as described in
several chronic pathological conditions (10, 15). Furthermore,
we have previously demonstrated that a proper macrophage
recruitment in muscle after an acute sterile damage is
also essential for maintaining a correct angiogenic program
and prevent the endothelial contribution to scar formation
(16). This seems to occur through a complex biological
process, referred to as endothelial to mesenchymal transition
(EndoMT). EndoMT involves loss of endothelial cell (EC)
identity in favor of a multipotent mesenchymal phenotype,
which often contributes to exacerbate the severity of many
different fibrotic disorders not only in the muscle but also
in kidney, liver and heart (17–19). Many recent studies have
suggested that ECs have the potential to differentiate along
other mesenchymal derived lineages, including chondrocytes and
osteogenic precursors (20–24).
Extra-skeletal osteogenesis is a sporadic event with serious
clinical consequences. Defined as heterotopic ossification (HO),
it involves the development of an endochondral bone in soft
tissues due to fracture complication, tissue injury, neurological
trauma or genetic defects, such as fibrodysplasia ossificans
progressiva (FOP, OMIM 135100) (25, 26). FOP arises from
gain-of-function mutations in the bone morphogenetic protein
(BMP) type I receptor gene ACVR1 (alias ALK2), resulting in
aberrant activation of the BMP signaling pathway and acquired
sensitivity to unconventional ligands of the mutated receptor
(27–29). Deregulation of the BMP pathway is also a feature of
acquired HO (30, 31). Lineage tracing studies have suggested that
several different cell populations may contribute to the ectopic
bone formation both in genetic and pharmacological models of
FOP, amongst which are ECs (32–37). Nonetheless, a definitive
endorsement of ECs as contributing to heterotopic ossification
remains controversial, partially due to the modest specificity or
efficiency of the lineage tracing tools used.
In this study, we rely on a specific and efficient in vivo
endothelial genetic tracing mouse model to unambiguously
demonstrate the contribution of EC-derived cells to BMP-
dependent ectopic chondro-ossification and to determine that
MPs play a non-redundant role in controlling this process.
RESULTS
EC-Derived Cells in the Regenerating
Skeletal Muscle Acquire an
EndoMT/Chondrogenic Gene Expression
Signature Upon Monocyte/Macrophage
Depletion
To study how the interplay between immune system and ECs
may contribute to trauma-induced heterotopic bone formation,
we chose a mouse model of severe muscle acute injury, where
macrophage infiltration is compromised. In this model, we
have previously shown that EndoMT and fibrosis are induced
(16). We generated double transgenic Cdh5CreERT2:R26REYFP
mice by crossing Cdh5CreERT2 transgenics with R26REYFP
reporters. By inducing the Cre activity at perinatal stages, this
mouse model guarantees very high efficiency and specificity of
the original labeling of endovascular progenitors and mature
ECs, thus excluding marking of any cell of mesenchymal
or hematopoietic lineages (16, 32, 38–40). In this model,
we have targeted MPs by intravenously injecting liposomes
containing clodronate (CLL) or PBS as control (Sham) 1 day
before and every other day after acute damage induction by
cardiotoxin (CTX) injection, and we freshly sorted EYFP+ ECs
from muscle of CLL- and Sham-treated mice 5 days after
CTX (Figure 1A), a time where we did not see yet major
changes in the EC-derived population, only a slight delay
in capillary re-organization (16). The monocyte/macrophage
depletion efficiency, as assessed by measuring the fraction of
CD11b+ and F4/80+ cells in peripheral blood of CLL- and Sham-
treated mice by flow cytometric analysis, was comparable to
our previous studies (Figure 1B, Supplementary Figures S1A,B)
(16, 40). This depletion per se did not affect the number of EC-
derived cells that could be retrieved (Figure 1C). In addition,
FACS analysis on EYFP+ sorted cells revealed that in both
Sham and Cll treated mice almost all the EYFP+ cells express
the endothelial marker CD31 (95,23 ± 2,56 and 96,56 ± 2,02,
n = 3). This is in agreement with the finding that all EC
(mature and progenitors) express Cdh5 and CD31, the latter
being expressed at lower levels in endothelial progenitors (38, 39)
(Supplementary Figures S2A,B). In both conditions, few cells
co-expressed CD31 and PDGFR-β, a PDGB receptor expressed
in pericyte but also in lymphatic and embryonic ECs and in
endothelial progenitors cells (32, 38, 41, 42). α7-integrin, marker
of mesenchymal and satellite cells, was not significantly expressed
(43) (Supplementary Figures S2A,B). These finding indicated
that our sorting strategy allowed us to obtain a population of
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FIGURE 1 | Gene expression profiling of EC-derived cells. (A) Experimental scheme of muscle acute injury and macrophage depletion (left panel). (B) Estimation of
the percentage of Cd11b+ and F4/80+ cells (macrophages) in the blood of clodronate (CLL) vs. control (Sham) treated mice (right panel), 5 days after injury. Bars
represent mean ± SEM. **p ≤ 0.01; ***≤0.001, n = 4. (C) EYFP+ gating strategy used for FACS analysis of single cell suspensions derived from CLL or Sham
Cdh5-CreERT2:R26R-EYFP mice. Plots are representative of at least three independent experiments. Graph on the right shows the quantification of the percentage of
EYFP+ sorted cells (EC derived cells). (D) Gene Ontology (GO) Biological Process terms enriched by differentially expressed genes (DEGs) found in CLL vs. control
samples. Number of up- and down-regulated DEGs associated to each term are shown as red and green bars, respectively. All the enrichments shown are
statistically significant (blue line indicates significance expressed as -log Pvalue). (E) Heatmap showing fold change in the expression of selected genes differentially
expressed between EC derived cells isolated from muscle of CLL- and Sham-treated Cdh5-CreERT2:R26R-EYFP mice, as assessed by RNAseq and qRT-PCR. (F)
qRT-PCR expression assays for a panel of selected genes. Values are expressed as fold changes relative to Sham mRNA expression and normalized on the
housekeeping (cyclophilln A). Bars represent mean ± SEM. *p ≤ 0.05; **≤0.01; ***≤0.001, n = 4.
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EC-derived cells devoid of significant contamination, suitable for
further bulk transcriptomic analysis.
We next characterized by next-generation sequencing (RNA-
seq) analysis the transcriptome profile of genetically labeled
isolated cells of endothelial origin (EYFP+ ECs). As a result,
we identified 1,399 genes that, just at 5 days after injury, show
a statistically significant differential expression (DEGs) between
CLL- and Sham-treated samples (Supplementary Table S1). The
Gene Ontology enrichment analysis showed, as expected, that
these DEGs are mainly involved in biological processes related
to EndoMT and mesenchymal-fibrogenic features (Figure 1D).
qRT-PCR analysis showed in CLL treated mice (Figures 1E,F),
a downregulation of genes encoding for endothelial surface
proteins (CD31, Cdh5, CD34), for signaling molecules (Notch4,
Flt4, Jag2) (32), and transcription factors (TCF4 and KLF4)
(44, 45) involved in endothelial differentiation. Conversely
EYFP+ cells from CLL treated mice upregulated genes coding
for mesenchymal/fibrogenic markers such as Collagen 1 and
Fibroblast activating protein (FAP) and for transcription factors
involved in EndoMT such as TWIST1 (19). Notably, in
cells from CLL treated mice we also found an enrichment
for genes involved in ossification and bone development
processes (Figure 1D). EYFP+ cells from CLL mice showed
upregulation of Sox9 and Runx2 (Figures 1E,F), master genes
of endochondral differentiation (46). These data suggest that
macrophage depletion not only promote EndoMT as shown
before, thus increasing endothelial plasticity (16, 40) but may also
enhance their chondro-osteogenic potential.
EC-Derived Cells Contribute to
BMP-Induced Chondrogenesis
To verify whether EC derived cells really contribute to the process
of ectopic chondro-ossification, we first induced the formation
of cartilage and bone in the muscle of Cdh5CreERT2:R26REYFP
or Cdh5CreERT2:tdTomato mice, by intramuscular injection of
rhBMP2, together with CTX, as described in Cappato et al. (47)
(Figure 2A). This HO model is a reasonable approximation for
HO in humans since it causes a highly reproducible sequence
of molecular signals and histological events, ultimately leading
to the emergence of endochondral bone, thus mimicking the
histological changes seen in both acquired HO and FOP (31,
36). After 7 days, we could detect the presence of EYFP+
ECs co-expressing the chondrocyte markers Sox9 and Runx2
(Figures 2B,C,F, Supplementary Table S2). Interestingly, many
EYFP+/Sox9+ cells expressed Ki67, indicating that they are
still proliferating and suggesting that Cdh5-derived cells do
not transdifferentiate directly to chondrocytes, but cell cycle
entry may be involved (Figure 2C). A number of EYFP+ cells
also express pSMAD1/-/5-/8 (Figures 2D,F), demonstrating they
have activated the chondrogenic pathway and display high BMP
signaling, suggestive of BMP type I receptor kinase activation
by rhBMP2. Interestingly, some EYFP+ pSMAD+ cells did not
express anymore the endothelial marker CD31 (Figure 2D).
On the other hand, after 10 days we could not detect EC-
derived cells expressing the osteogenic master gene Osterix (Osx)
(Figure 2E), showing that in these conditions EC-derived cells
did not contribute to ectopic ossification. These results are
indicative that upon enhancement of BMP signaling, coupled
with a muscle injury, ECs show the potential to contribute to the
formation of ectopic cartilage.
Macrophage Depletion Exacerbates
BMP-Induced Ectopic Ossification and
Conversion of EC-Derived Cells
to Chondrocytes
Infiltrating MPs prevent EndoMT upon acute muscle damage
(16) and, as demonstrated above, macrophage depletion per
se is sufficient to induce the transcriptional upregulation of
the chondrocyte markers Sox9 and Runx2 in EC-derived
cells (Figure 1D). In contrast previous studies reported that
depletion of circulating phagocytes decrease ossification in
transgenic FOP end neurological HO (48, 49). To explore
and further clarify the role of infiltrating MPs during
BMP-induced HO, we experimentally depleted phagocytes
by intravenously injecting liposomes containing CLL (or
PBS as control, Sham) every 2 days in BMP/CTX-treated
Cdh5CreERT2:R26REYFP or Cdh5CreERT2:tdTomato mice
(Figure 3A). In this condition as well, Cd11b+ and F4/80+
cell count in peripheral blood was reduced in CLL- vs. Sham-
treated mice (Supplementary Figures S3A,B). Importantly,
we showed that this treatment led to a significant decrease
in the number of F4/80+ MPs that infiltrate the muscle
(Supplementary Figures S4A–C), thus indicating that phagocyte
targeting was really effective on the local population. In particular
we observed a significant decrease in the number of F4/80+
macrophages also expressing the specific markers of alternative
activation CD163 (Supplementary Figures S4A,C) and CD206
(Supplementary Figures S4B,C).
We first focused on the fate of EC-derived cells at early
stages of chondro-ossification, by freshly isolating them from
the muscle 7 days after BMP/CTX treatment (Figure 3B).
dtTomato+ EC-derived cells from CLL-treated mice showed an
increased expression of Sox9 gene with respect to control samples
(Figure 3C). On the other hand, the dtTomato− fraction in CLL-
treated mice showed the upregulation of Bmp4 and Bmp6 gene
expression, suggesting that MPs depletion leads to amplification
of BMP signaling in the muscle (Figure 3C). This is consistent
with an increased hypoxic environment as suggested by trend
in α the upregulation of HIFa transcripts (Figure 3C) and in
agreement with previous studies (50).
Immunofluorescence (IF) analysis confirmed that, 7 days
after BMP/CTX injection, muscle from CLL mice contains an
increased number of EC-derived cells (EYFP+ or dtTomato+)
expressing Sox9 protein (Figure 3D).
Only in this condition we also observed that, 10
days after BMP/CTX, few EC-derived cells express Osx
(Supplementary Figure S5A), indicating that some of these cells
have the potential to enter an osteogenic fate. After 21 days some
EC-derived cells also co-localize with the extracellular marker of
mature osteoblast Osteocalcin (Supplementary Figures S5B,C).
In vivo micro-computerized tomography (µCT) scan was
carried out on both CLL- and Sham-treated mice to assess
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FIGURE 2 | EC-derived cells contribute to the development of ectopic bone. (A) Experimental scheme of BMP2-mediated bone induction. (B–D) IF of muscle section
from quadriceps of Cdh5-CreERT2:R26R-EYFP mice at 7 days after bone induction and stained with Runx2 and EYFP antibodies (B), Sox9, EYFP and Ki67
antibodies (C) or pSMAD1/5/8, EYFP and CD31 antibodies (D). Right panels showed merged images, where nuclei are stained with DAPI (blue). In B arrows indicate
cells that co-express both Runx2 and EYFP. Inset show magnification (3×) of double positive cells. In C, arrows indicate cells that co-express both Sox9 and EYFP,
insets show magnification (3×) of cells expressing Sox9 and EYFP, or Sox9, EYFP, and Ki67. In D arrows and insets with magnification show pSMAD1/5/8+ cells of
endothelial origin (EYFP+) that have lost CD31 endothelial marker. (E) IF of muscle section from quadriceps of Cdh5-CreERT2:dtTomato mice at 10 days after bone
induction and stained with Osterix (Osx) antibody. Right panel shows merged images, where nuclei are stained with DAPI (blue). No double positive dtTomato+/Osx+
were detected in this condition. Magnification 40×. Scale bars for all panels, 50µm. (F) Quantification of the number of total number of Runx2+, Sox9+ or
Smad1/5/8+ cells/mm2 and the number of EYFP double positive cells (Sox9+/EYFP+, Runx2+/EYFP+, pSmad1/5/8+/CD31+/EYFP+ ).
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FIGURE 3 | Macrophage depletion increases EC-derived cells contribution to endochondral differentiation. (A) Experimental scheme showing BMP2-mediated bone
induction, clodronate (CLL) and Sham liposome treatments, and sacrifice time-points. (B) Gating of tdTomato+ sorted cells from Cdh5-CreERT2:dtTomato mice
quadriceps at 7 days after bone induction (left). On the right: graph showing the median percentage of dtTomato+ cells among the number of living cells (gated on
physical parameters) in Sham and CLL-treated mice. Bars represent mean ± SEM (n = 4). (C) qRT-PCR expression of Sox9 in dtTomato− cells (left) and of Bmp4 and
Bmp6 in dtTomato+ cells (right), isolated from CLL or Sham Cdh5-CreERT2:dtTomato mice quadriceps at 7 days after bone induction. Data are expressed as fold
changes relative to Sham mRNA expression and normalized on the housekeeping (cyclophillin A and/or 28S) (left). Bars represent mean ± SEM. *p ≤ 0.05; **≤0.01
(n = 4). (D) Sections of quadriceps of CLL and Sham Cdh5-CreERT2:R26R-EYFP mice at 7 days after HO induction. Panels show IF images of muscle sections
stained with Sox9 and EYFP antibodies. Right panels showed merged images, where nuclei are stained with DAPI (blue). Scale bar 50µM. Panel magnification 40×.
Arrows and inset with magnification (3×) indicate cells that express both markers. Graphs on the right represent the number of Sox9+EYFP+ cells/mm2. Bars
represent mean ± SEM. *p ≤ 0.05 (n = 4).
the progression of ossification and any other effect on the
normal skeletal structure at later stages (10, 21, and 30 days
after BMP/CTX treatment) (Figure 4A). After 10 days, we could
already detect significant differences in HO in CLL vs. control
mice (measured as mineralized volume, mm3), although not
in bone density (HU/mm3) (Figures 4C,D). Twenty one days
after bone induction µCT scans showed a significant increase
in both HO volume and bone density in CLL vs. control mice
(Figures 4C,D, Supplementary Movies S1, S2). The significant
difference in HO volume was maintained also at 30 days after
treatment. Bone density was increased in CLL mice at 30 days,
but with higher variability (Figures 4B,D). These results were
confirmed by histochemical analysis using hematoxylin and
eosin (H&E) and Masson staining, which revealed that, at both
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21 and 30 days after HO triggering, the ectopic bone area
appeared greater in CLL- vs. Sham-treated mice (Figures 4E,F).
This implies that proper immune cells infiltration from the
beginning of HO triggering is able to limit the extent of the
ectopic bone lesions. In addition, in vivo µCT imaging also
allowed us to show that only in CLL-treated mice there was an
increase of fluorescence signal in the area of ectopic ossification
at 10 and 21 days after BMP-induction, reflecting an increased
recruitment of EC-derived cells upon macrophage depletion
(Supplementary Movie S3), in agreement with previous studies
showing that circulating ECs are recruited to the wound/HO site
and undergo EndoMT (51).
Finally, we wanted to assess whether we could prevent the
exacerbated bone formation developed upon macrophage
depletion. Since altering the population of infiltrating
macrophages led to an amplification of BMP signaling, and
the targeting of this pathway has been suggested as a potential
therapy for HO (52) we decided to treat Sham- or CLL-treated
mice with dipyridamole, a drug that has an inhibitory effect
on the whole SMAD-dependent BMP signaling pathway
and partially inhibits the process of BMP-triggered HO (47)
(Figure 5A). We first verified that dipyridamole did not lead
to a differential CD11b+ monocyte depletion in CLL mice
(Figure 5B). We therefore compared the extent of HO in Sham-,
Sham/dipyridamole-, CLL-, and CLL/dipyridamole-treated mice
by µCT and histochemistry (Figure 5C), and found that after 21
days dipyridamole was able to rescue HO in CLL mice (and in
Sham treated mice as also previously reported) (47), reducing the
mineralized bone volume and bone density to levels comparable
to those of Sham mice (Figures 5D,E).
DISCUSSION
Heterotopic ossification (HO) is a pathological condition where
extra-skeletal bone forms in soft tissues due to extreme trauma
or genetic defects. Induction of ectopic bone formation is
highly destructive. Therefore, its prevention has become an
important focus of research, particularly with regards to pre-
and post-operative preventive care in acquired heterotopic
ossification and in fibrodysplasia ossificans progressiva (FOP)
patients. Of particular relevance is the research aiming to
identify the pathophysiological mechanisms of HO, thus
eventually contributing to the development of new and targeted
treatment options.
FOP is caused by mutations of the ACVR1 gene, encoding the
ALK2 bone morphogenetic protein (BMP) type 1 receptor, and
the consequent dysregulation of the BMP/Activin/TGF-ß family
ligand signaling is a shared property of both genetic and acquired
forms of HO (30, 31). Furthermore, the sequence of histological
events leading to the formation of the ectopic endochondral
bone is similar in the two conditions. Accordingly, it has been
suggested that HO in FOP and in non-genetic conditions might
be mediated by common effectors and progenitor cells (34).
In the last years, several studies have focused on the cellular
origin of ectopic ossification and potential candidates have
shown osteogenic potential both in vitro and in vivo (34–37,
51, 53, 54). Endothelial involvement in induced and genetic HO
is still actively debated (55–57). Early lineage tracing studies
indicated Tie2-expressing vascular cells as the leading candidates
for the cellular origin of BMP2-mediated heterotopic cartilage
and bone (36). It has been recently shown that the main
Tie2+ cells contributing to ectopic chondro-ossification in a
transgenic model of FOP carrying the ACVR1R206 mutation are
fibroadypogenic precursor cells (FAP) (57). This same study
overruled the contribution of bona fide ECs to cartilage or bone
formation on the basis of a VE-Cadherin dependent lineage
tracing murine system, different from the one we used, first
described in Alva et al. (58). In this transgenic line labeling
efficiency in adult skeletal muscle has never been properly
evaluated and quantified (39), therefore underestimation of EC
contribution to endochondral ossification is possible.
By taking advantage of an efficient and endothelial-specific
genetic lineage tracing mouse system (16, 38–40), we have
followed the fate of ECs and their progeny in pathological
chondro-osteogenesis leading to ectopic bone formation. We
show here that EC-derived cells show the potential commitment
to the chondrogenic lineage upon EndoMT induction in
the skeletal muscle. Furthermore, upon BMP2 stimulation,
muscle EC-derived cells express pSMAD1-5-8, indicating
that the BMP pathway has been activated in these cells,
and started to express Sox9 and Runx2, master factors of
chondrogenesis (46), while downregulating endothelial markers,
such as CD31.
EndoMT has been previously proposed to contribute to early
phases of HO (51, 54, 59) and inhibition of EndoMT could
rescue HO in vivo and in vitro (59). It has been suggested
that the “transition” to a mesenchymal state in EndoMT and
in Epithelial to mesenchymal transition (EMT), could indeed
favor the acquisition of “stem-like” properties. While this has
been fully demonstrated only for the process of (EMT) (60), it
could account for many observation regarding ECs, including
the co-expression of stem, endothelial and mesenchymal marker
and their plasticity to differentiate to various lineages in both
physiological and pathological conditions (18, 61). Some of
the EC-derived cells derived cells expressing Sox9 are still
proliferating, indicating that it is not a direct endothelial to
chondrocyte conversion, but the process may require a step
through a stem/progentitor state.
Another aspect to be considered when evaluating and
comparing the EC-derived cells contribution to induced and
genetic HO is the presence of the recurrent ACVR1R206H
mutation. It is quite predictable that mutation in the ACVR1
(alias ALK2) locus would greatly impact the response and fate
of all potential chondro-osteogenic progenitors. Indeed, iPS
derived EC from FOP patients showed increased SMAD1/5/8
signaling and early chondro-osteogenic differentiation upon
BMP4 stimulation (chondrocytes and immature osteoblasts),
even if they could not differentiate in mature osteoblasts (20).
Our results indicate that in a “wild-type” environment, BMP
activation can convert a number of “wild-type” EC-derived cells
in chondrogenic precursors cells, that, regardless of whether they
are bipotent osteo-chondroprogenitors or not, can contribute to
the process of ectopic endochondral ossification (62).
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FIGURE 4 | Macrophage depletion increases BMP2 mediated HO. (A) Experimental scheme showing BMP2-mediated bone induction, clodronate (CLL) and Sham
liposome treatments, and micro-computerized tomography (µCT) time-points. (B) µCT scans of CLL or Sham Cdh5-CreERT2:tdTomato mice at 10, 21, and 30 days
after bone induction. (C) Quantification of the mineralized ossicle volume (mm3). n = 4 mice. Box and whisker plots represent mean and min to max values. *p ≤
0.05; **≤0.01. (D) Quantification of the ectopic bone density (HU/mm3). n = 4 mice. Box and whisker plot represent mean and min to max values. **p < 0.01. HU,
Hounsfield unit. (E,F) H&E and Masson Trichrome staining of muscle section showing lesions in Sham or CLL Cdh5-CreERT2: tdTomato mice at 21 and 30 days after
bone induction. Scale bar 50µm.
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FIGURE 5 | Dipyridamole decreases HO induced by macrophage depletion. (A) Experimental scheme showing BMP2-mediated bone induction, clodronate (CLL) and
Sham liposome treatments, dipyridamole administration and micro-computerized tomography (µCT) time-points. (B) Graph representing the percentage of Cd11b+
cells after Sham, Sham/dipyridamole (Sham+Dipy), CLL or CLL/dipyridamole (CLL+Dipy) treatment. n = 5 mice. Bars represent mean ± SEM. (C) µCT scans of
(Continued)
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FIGURE 5 | Cdh5-CreERT2:tdTomato mice treated with CLL (BMP2/CLL) or CLL/dipyridamole (BMP2/CLL/Dipy), PBS (BMP2/Sham) or PBS/dipyridamole
(BMP2/Sham/Dipy) at 21 days after bone induction. Lower panels show representative images of bone lesions in muscle sections after H&E and Masson Trichrome
staining. Scale bar 50µm. (D) Quantification of the mineralized ossicle volume and (E) of the ectopic bone lesion density (HU/mm3) (right). Box and whisker plots
represent mean and min to max values. *p ≤ 0.05; ***≤0.001 (n = 5).
Notably we show that EC-derived cell differentiation toward a
chondrogenic lineage increases if the inflammatory environment
is affected, and this is followed by an exacerbated ectopic
bone formation.
The role of cells of the innate and adaptive immune
system of in physiological ossification and HO has always been
regarded as crucial (63–65). A particular focus has been set
on the role of MPs, since they play a crucial function in
tissue remodeling (13). A generalization of what is in vivo a
broad and partially continuum set of differentiating populations
suggests that activated MPs generate M1 (“classically activated”)
and M2 (“alternatively activated”) cells (66). M1 macrophages
are mainly involved in the response against pathogens, while
M2 macrophages in the later phases of inflammation, and
tissue regeneration and adaptation (66, 67). M2 cells play also
angiogenic and vascular protective roles in inflamed tissues (66,
67). Indeed, we and others have demonstrated that MPs are
necessary to orchestrate proper tissue remodeling and repair
upon muscle injury, also by favoring angiogenesis, via the
production of several secreted mediators and counteracting
EndoMT (16, 68).
However, MP role might be more complex since it is
becoming clearer that MPs are far more heterogeneous
than what predicted before (69). It has been demonstrated
for example that depletion of differentiated macrophages
promoted an osteogenic environment whereas depletion of
early lineage macrophages resulted in osteopenia (70, 71).
Phagocyte/monocyte depletion was also found to counteract
ectopic ossifications in models of Neurological HO and FOP
(48, 49, 72). Still the characterization of remaining phagocytes
in the soft tissues where HO was occurring has never been
performed in these latter studies, therefore it is not clear what
was the depletion magnitude in situ and which populations
were depleted.
In our model not only we can achieve a 50–60% depletion
of circulating CD11b+/F4/80+ monocytes in agreement with
our previous findings (16, 40), but we can also show a 2–3
fold decrease in the number of F4/80+ macrophages infiltrating
the muscle upon CLL treatment. Furthermore, we show that
that amongst the depleted cells many are alternatively activated
macrophages, e.g., the ones recognized to play a role in
supporting proper muscle healing and angiogenesis (67).
It has been shown that in a model of NHO induced by spinal
cord injury, that triggers a massive infiltration of inflammatory
monocytes (Ly6Chigh), CLL treatment could lead to increased
HO (73). Conversely, depletion of infiltrating macrophages,
in particular of alternatively activated populations, in a
BMP2/injury HO model, correlated with an increased EndoMT,
increased chondrogenesis of EC precursors, and exacerbated
bone lesion. It is conceivable that these apparently discrepant
finding, may result from a different immune environment at the
ossification site due to the different HO trigger and consequently,
the different effect of the depletion, and also others phagocytic
cells may be depleted with this approach.
CLL treatment lead to sustained BMP signaling. Despite the
fact that we cannot univocally pinpoint the cellular source of
BMP, this enhanced signaling may correlate with an increase in
expression of hypoxia inducing factors as also shown before (16).
This is also in agreement with previous work demonstrating that
hypoxia is a promoting factor for HO, through amplification
of BMP signaling (50). Indeed, we were able to partially
inhibit HO in our model system by administration of the
ACVR1/BMP/SMAD inhibitor dipyridamole, confirming that
sustained BMP signaling plays a key role inducing HO in our
monocyte depleted model.
Further studies will be necessary to get more insight in the
signaling events underlying the crosstalk between the different
osteoprogenitor cells, macrophages and other immune cells
remaining in the osteogenic niche after depletion. This would
allow the identification of agents that selectively sustain those
immune cells that directly or indirectly protect from acquired
and hereditary HO, as a more valuable strategy with respect to
a general anti-inflammatory approach.
MATERIALS AND METHODS
Animals
Mice were housed in the SPF facility at San Raffaele Scientific
Institute (Milan, Italy) and treated with the approval of the
Institutional Animal Care and Use Committee (IACUC 489,
663). Cdh5-CreERT2 (74) and R26R-EYFP (75) or tdTomato (76)
mice were bred to yield heterozygous siblings and genotyped as
in Wang et al. (74). Cre recombination was induced in Cdh5-
CreERT2:R26R-EYFP or Cdh5-CreERT2: tdTomato mice at post-
natal days 6-7-8 with three subcutaneous injections of Tamoxifen
(250 µg/mouse; Sigma-Aldrich, St. Louis, MO, USA).
Depletion of Circulating Phagocytes
Three months old Cdh5-CreERT2:R26R-EYFP or Cdh5-
CreERT2: tdTomato mice were injected intravenously (i.v.)
with liposomes containing either clodronate (CLL; 1.8
mg/mouse) or PBS (Sham) (http://www.clodronateliposomes.
org/ashwindigital.asp?docid=26). The treatment was performed
1 day before cardiotoxin (CTX) injection (5 µl CTX 100µM,
from Naja mossambica mossambica, Sigma-Aldrich, Buchs, SG,
Switzerland) and every 3 days afterward (at 2, 5, 8, 11, 14, 17, and
20 days after CTX injection).
Flow Cytometry
EYFP+ and Tomato+ EC-derived cells from Cdh5-
CreERT2:R26R-EYFP and Cdh5-CreERT2:tdTomato mice,
respectively, were isolated from adult mice after muscle
dissection. Tissues were cut in small pieces and dissociated
with 0.15 mg/ml Collagenase IV (Roche, Basel, Switzerland)
Frontiers in Immunology | www.frontiersin.org 10 July 2019 | Volume 10 | Article 1640
Tirone et al. Macrophage Counteract HO and EC-Derived Chondrogenesis
and 0.25% Trypsin (Gibco, Thermo Fisher Scientific, Waltham,
MA, USA) or 0.4 mg/ml Dispase (Gibco). Dissociation reaction
was performed at 37◦C for 30min for 2–3 cycles. Resuspended
mononucleated cells were filtered with 70 and 40µM filters.
Cells were suspended in either DMEM with 20% FBS, 20mM
HEPES, 2mM EDTA or PBS with 2% FBS, 2mM EDTA (for
antibody staining). For FACS analyses on circulating cells,
blood was retrieved from the mouse tail, washed with red lysis
buffer and incubated at 4◦C for 30min in blocking solution
(PBS with 2% FBS, 2mM EDTA). Cell sorting was performed
using the MoFLoXDP (Beckman Coulter, Inc., Brea, CA, USA)
or FACSAria Fusion (BD Biosciences, Bedford, MA, USA).
FACS analysis was carried out using the BD FacsCANTO II
(BD BioscienceUSA). Data were analyzed by FlowJo (TreeStar)
and/or FCS Express 6 (De Novo Software, Los Angeles, CA,
USA). The antibodies used are listed in Supplementary Table S3.
Histochemistry, Immunohistochemistry,
and Immunofluorescences
Serial muscle sections were stained with H&E (Sigma-Aldrich),
according to standard procedures. Muscle sections were stained
with H&E or Masson Trichrome (Bio-Optica, Milan, Italy),
according to the manufacturers’ instructions.
Immunohistochemistry (IHC) was performed on muscle
frozen sections fixed with 4% PFA treated with 0.3% H2O2
and with an avidin-biotin blocking kit (Vector Laboratories,
Burlingame, CA, USA), according to the manufacturer’s
instructions. Sections were blocked with 5% BSA, 0.1%
Triton and 10% donkey serum in PBS for 1 h at RT.
Subsequently, sections were incubated O/N with primary
antibody. Primary Ab was revealed using biotin-conjugated anti-
rat (1:300) IgG (eBiosciences, San Diego, CA, USA) and HRP
streptavidin (Vector Laboratories), and detected using Vector
NovaRED substrate kit (Vector Laboratories). Specimens were
counterstained with DAPI (Molecular Probes, Life Technologies,
Carlsbad, CA, USA) and examined with a Nikon Eclipse 55i
microscope (Nikon, Tokyo, Japan). Immunofluorescence (IF) on
frozen section was carried out as in Zordan et al. (16). The
antibodies used are listed in Supplementary Table S4. Images
were acquired using the following microscopes: Leica TCS SP2
Laser Scanning Confocal or Zeiss LSM 710 Confocal Microscope.
Images were processed using Adobe Photoshop CS6 and
Adobe Illustrator CS6. For quantification of chondroosteogenic
cells, at least 7 fields were acquired for sample, cells positive
for a chondrogenic or osteogenic markers (Sox9, Runx2,
Osterix, SMAD1-5-8) and cells co-expressing reporter gene
and chondrogenic or osteogenic markers were counted. For
quantification of macrophages, at least 6 fields were acquired for
sample, cells positive for an F4/80 and cells co-expressing CD163
or CD206 were counted. DAPI negative cells were excluded
from quantification.
Transcriptome Sequencing (RNA-seq)
Total RNA samples were extracted from freshly sorted EYFP+
EC derived cells of muscle of CLL- and Sham-treated mice
using ReliaPrepTM RNA Cell Miniprep System (Promega,
Milan, Italy), checked for integrity on 2200 TapeStation
instrument (Agilent Technologies, Santa Clara, CA, USA)
and stored at −80◦ until use. Starting from 200 ng total
RNA, RNA-seq libraries were prepared using the Illumina
TruSeq Stranded mRNA Library Prep Kit (Illumina, San
Diego, CA, USA), according to manufacturers’ instructions, and
sequenced on MiSeq platform (Illumina) in 76-cycle paired-
end runs. Three independent replicates were sequenced for
each condition (CLL and Sham). Raw sequence data are
available in NCBI Short Reads Archive (SRA) under Accession
Number PRJNA471032.
After fastq quality control by using FastQC tool, raw reads
were mapped to the mouse reference genome (Mus musculus
UCSC mm10/GRCm38) using STAR aligner (v.2.3.1s) and gene
counts were calculated by HTSeq (v.0.6.1), using the Gencode
M12 GTF file as gene model.
Differential gene expression analysis was carried out using
DESeq2 software (v.1.0.17) to perform a pairwise comparison
between CLL vs. Sham replicates. Low expressed genes (mean
normalized count across all samples < 10) were filtered out
before testing genes for statistical significance. A False Discovery
Rate [FDR, Benjamini and Hochberg (BH) correction] < 0.05
was used as cut-off to define statistically significant differentially
expressed genes (DEGs) in CLL vs. Sham samples. DEGs with
log2 fold change > 0 were flagged as up-regulated, while genes
with log2 fold change< 0 were flagged as down-regulated in CLL
vs. Sham samples.
ToppGene suite was used to perform gene enrichment
analysis of statistically significant DEGs for Gene Ontology
(GO) categories and pathways (https://toppgene.cchmc.
org/enrichment.jsp). An FDR (BH correction) < 0.05 was
applied to all the annotation terms to defined statistically
significant enrichment.
Quantitative Real-Time PCR
Reverse transcription (RT) was done using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). qRT-PCR analysis was carried out using the
LightCycler 480 Instrument (Roche) or the 7900HT FAST Real-
Time PCR detection system (Applied Biosystems). cDNAs were
amplified using the GoTaq qPCR Master Mix and the Hot
Start Polymerase (Promega). Primer sequences are listed in
Supplementary Table S5. Ct values >35 were considered as
negative. Each data points for every biological replicate was
analyzed in triplicate. Quantification was performed using the
relative 1Ct method. 28S or cyclophilin A genes were used as
internal controls.
In vivo Heterotopic Ossification
0.1 µg/µl of rhBMP2 (Peprotech, Rocky Hill, NJ, USA) in
100 µl growth factor-reduced Matrigel (BD Biosciences, 1:100
dilution) were injected intramuscularly in the quadriceps of
Cdh5-CreERT2:R26R-EYFP or Cdh5-CreERT2: tdTomato 3-
month-old mice. The contralateral muscle was used as internal
control and injected withMatrigel only. Both quadriceps muscles
were injected with 5 µl CTX 100µM (from Naja mossambica
mossambica, Sigma-Aldrich, Buchs, SG, Switzerland) to increase
muscle damage. Animals were anesthetized by inhalation of
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2-bromo-2-chloro-1,1,1-trifluoroethane, ≥99% (Sigma-Aldrich)
before the injection.
In vivo Micro-Computerized Tomography
Imaging of Heterotopic Ossification
At day 10, 21 and 30 after BMP injection, in vivo micro-
computerized tomography (µCT) scans were carried out to
assess progression of ossification and any other effect on the
normal skeletal structure. In vivo µCT imaging was performed
using the IVIS SpectrumCT Pre-clinical in Vivo Imaging
System (Perkin-Elmer, Waltham, MA, USA). µCT images were
acquired without any contrast medium, with the following
parameters: x-ray tube voltage = 50 kV, tube current = 1mA,
x-ray focal spot size = 50µm. The µCT images calibrated
in Hounsfield unit (HU) were reconstructed with a voxel
size of 75 µm3. Threshold-based image segmentation was
performed to obtain a 3D reconstruction and quantification of
the ossification.
The total mineralized volume V = N × voxel size (mm3)
was quantified usingMIPAV (Medical Image Processing Analysis
and Visualization) and MATLAB software, where N is the
number of voxels corresponding to bone derived from the image
segmentation procedure. The bone density (BD) quantification
was calculated using the following formula:
BD =
∑N
i=0HUi
V
(1)
The IVIS SpectrumCT was also used to obtain 3D fluorescence
images using a transillumination excitation source placed below
the animal. More precisely, a set of 2D fluorescence images
were acquired at different transillumination points within
the region of interest. 3D images were then reconstructed
using the Fluorescence Imaging Tomography (FLIT) algorithm,
as described in Kuo et al. (77), and implemented in the
Living Image 4.5 software (Perkin Elmer). Transillumination
fluorescence images were acquired using the following setting:
excitation filter = 570 nm, emission filter = 620 nm, f-
stop = 2, camera binning = 8, exposure = auto, field
of view= 13 cm.
Dipyridamole Treatment
Ten milligram per kilogram (body weight) dipyridamole was
intraperitoneally (i.p.) administered daily to the treated animals
in a solution composed of 10% ethanol, 5% 2-pyrolidone, 12–
15% propylene glycol, 10% Cremophor ELP, saline to 100% as in
Cappato et al. (47).
Statistical Analysis
The number of animals needed to obtain statistically reliable
data was calculated on the basis on published previous work
carried out in our laboratory (16, 47) to minimize the number
of animals used avoiding both an excess of animals used for
each experiment and unnecessary repetitions and ensuring that
each experiment produces meaningful data according to the
principles of the 3Rs (Replacement, Reduction, and Refinement).
The subjects allow to highlight differences between groups as
regards the differences inmacrophage depletion, gene expression,
EC-cell counting and contribution to the various lineages of at
least one standard deviation, with a power of at least 80% (error
alpha = 0.05). Data were analyzed with Microsoft Excel 14.1.0
and GraphPad Prism 6 and were plotted as mean ± standard
deviation (SD) or mean ± standard error of mean (SEM) or
mean and min/max values. To evaluate statistical significance,
unpaired two-tailed Student‘s t- tests were used assuming
equal variance. Differences among three different experimental
groups were evaluated by ANOVA analysis with Bonferroni as
post-hoc tests.
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Movie S1 | 3D µCT reconstruction of the HO in BMP2/Sham treated
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reconstruction is representative of at least three independent experiments.
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tdTomato mice. The 3D reconstruction is representative of at least three
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